SVB Leerink Reiterates Outperform Rating on Cogent (COGT), 'We believe that the bezuclastinib dataset will be a meaningful catalyst for shares'
Tweet Send to a Friend
SVB Leerink analyst Andrew Berens reiterated an Outperform rating and $14.00 price target on Cogent (NASDAQ: COGT)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
